EU UV Filter Approvals: Why Sunscreen Brands Are Still Waiting — and What Annex VI Compliance Actually Requires in 2026

The EU’s positive list principle for UV filters is one of those regulatory design choices that looks straightforward in a legal text and creates genuine chaos in a formulation lab. The rule itself is simple: if a UV filter isn’t listed in Annex VI of Regulation (EC) No 1223/2009, it cannot appear in your product. Not provisionally. Not pending review. Not with a transition period. It simply cannot be there.

Annex VI currently lists around 28 permitted UV filters, each entry specifying a maximum concentration and, in many cases, conditions on product type or mandatory labelling. That number sounds generous until you consider how long the list has taken to reach this point — and how many innovative filters with years of global commercial use still sit outside it.

For European sunscreen brands, and for the non-EU manufacturers seeking EU market entry, understanding why this gap exists and what to do about it is not a regulatory curiosity. It’s a core product development constraint.

How a UV Filter Gets Added to Annex VI — and Why It Takes So Long

The approval pathway is multi-actor and genuinely slow. It starts when a company — typically the ingredient manufacturer — submits a dossier to the European Commission arguing that a substance should be permitted under Annex VI, or that the conditions attached to an existing entry should be modified. From that submission, the Commission refers the request to the Scientific Committee on Consumer Safety (SCCS), the independent scientific body responsible for evaluating ingredient safety in cosmetics.

The SCCS review is thorough. The committee assesses toxicological data, dermal absorption studies, systemic exposure estimates, genotoxicity profiles, and — for UV filters specifically — photostability data and the potential for endocrine disruption. For complex molecules or where the available data contains gaps, the SCCS routinely requests additional studies before finalising its opinion. That back-and-forth can add another 12 to 18 months to an already lengthy process.

Once the SCCS issues a favourable opinion, the Commission drafts an amendment to the Regulation — either a delegated act or an implementing regulation, depending on what’s being changed — and that instrument goes through its own consultation and scrutiny cycle before entering into force. Start to finish, the realistic minimum timeline for a complete, well-documented application to result in a Commission Decision adding a filter to Annex VI is five to seven years. Some have taken considerably longer. A brand that submits a full dossier today should not plan its 2029 launch around an ingredient that hasn’t yet cleared the SCCS stage.

This timeline reflects genuine scientific rigour, not bureaucratic sloppiness. The EU’s precautionary approach to ingredient approval is a feature, not a bug — particularly for substances with direct skin contact and potential systemic absorption. But it does create a structural tension with the innovation cycle. And brands that don’t understand the pipeline end up with formulations that can’t go to market.

The Divergence Between EU-Approved and Globally Available UV Filters

The widest gap between EU-permitted and globally available filters sits in the UVA space. Several high-performance broad-spectrum filters that have become formulation staples in the US, Japan, South Korea, and Australia have spent years in the EU pipeline or have not yet reached full market authorisation across all product types.

The contrast with the United States is instructive but often misread. The FDA’s sunscreen monograph system — which predates the modern era of UV filter chemistry — has historically been even slower than Brussels in approving new active ingredients. Ecamsule (Mexoryl SX), for example, is authorised in the EU at up to 10%, but gained only a narrow FDA clearance years after its European approval. Bisoctrizole (Tinosorb M) and bemotrizinol (Tinosorb S) — both broad-spectrum filters with strong UVA coverage — appear in EU Annex VI but remain unapproved in the United States despite having years of post-market data.

The practical implication: a product formulated for the EU market using these filters is not automatically compliant for US export. A brand building a dual-market product — Europe and North America — cannot simply choose one formulation and apply it globally. You need separate INCI declarations, often separate formulations, and in some cases entirely different supply chains for UV actives. We see this constraint hit hardest at the premium end of the market, where brands want to lead with novel photoprotection claims in every territory simultaneously. That ambition runs directly into the reality of non-harmonised approval lists.

Brands entering Canada face a similar but distinct challenge. Health Canada’s sunscreen monograph (under the Natural and Non-prescription Health Products Directorate) has its own approved list of UV filters and its own concentration ceilings. A filter permitted in both the EU and the US may still require a separate review before a product can be placed on the Canadian market.

What Annex VI Compliance Actually Requires from Your Technical File

Being permitted on Annex VI is a necessary condition, not a sufficient one. The entry for each UV filter specifies the conditions under which it may be used. Getting any of those parameters wrong creates a non-compliance regardless of whether the substance itself is approved.

Several areas where we consistently see errors in the Technical Files and CPNP notifications we review:

Concentration arithmetic on multi-filter formulas. Annex VI maximum concentrations apply per substance in the finished product, not in aggregate. A formula combining, say, 4% butyl methoxydibenzoylmethane, 7.5% ethylhexyl methoxycinnamate, and 3% benzophenone-3 requires verification of each substance individually against its Annex VI ceiling. There is no provision for blending or averaging across filters. Each must sit within its own limit.

Product-type restrictions. Some Annex VI entries condition the permitted concentration on whether the product is rinse-off or leave-on. A maximum concentration that applies to a sunscreen lotion may not apply to a rinse-off shower gel with sun protection claims. This distinction is frequently overlooked when a formula is reformulated across product categories.

Mandatory label disclosures. Benzophenone-3 (oxybenzone), listed in Annex VI at a maximum of 6%, carries a mandatory labelling requirement: the phrase “contains benzophenone-3” must appear on the outer packaging beyond the standard INCI ingredient list. This is an affirmative warning statement, not simply an ingredient declaration. We see it missed regularly on products entering the EU from manufacturers who are accustomed to non-EU labelling conventions.

INCI naming consistency across documentation. Annex VI entries use INCI nomenclature as identifiers. If your Product Information File (PIF), CPNP notification, and outer packaging declaration use different names or spellings for the same UV filter — whether from a legacy trade name or a supplier SDS that uses an outdated designation — you create a documentation inconsistency that flags during national competent authority reviews, including those conducted by France’s ANSM or DGCCRF.

The SPF Claim Layer That Sits Above Annex VI

Here’s a complication that catches brand compliance teams off guard: Regulation (EC) No 1223/2009 governs which UV filters you can use and under what conditions. It does not directly govern the SPF number on your label. That claim is addressed by Commission Recommendation 2006/647/EC, a non-binding but widely applied framework that references specific minimum protection thresholds and directs brands to validated test methodologies.

The reference test methodology for in vivo SPF determination is ISO 24444:2019. If you’re relying on SPF data generated under the US FDA monograph testing protocol — or under an earlier version of the ISO method — that data may not be considered adequate by EU market surveillance authorities. Several brands have arrived at pre-launch review stage only to discover that their existing SPF testing report needs to be supplemented or replaced entirely with ISO 24444-compliant methodology.

A full SPF test involving a human panel under ISO 24444:2019 conditions — recruitment, irradiation protocol, report generation — typically runs eight to twelve weeks. Discovering the gap during final launch preparation rather than at the formulation validation stage is an expensive schedule problem. The test cost itself is manageable; the delay rarely is.

Building a Sunscreen Formulation Strategy That Accounts for Regulatory Reality

The practical answer is front-loading the regulatory check before formulation investment begins. Before a UV filter goes into a prototype, verify its Annex VI status against the current consolidated text of Regulation (EC) No 1223/2009 — including any amendments adopted since the version you last referenced. Not the INCI database. Not a supplier’s marketing sheet. The actual legislative text.

If you’re building for multiple markets simultaneously, map the UV filter approval matrix across all target territories at the start. Some filters that work cleanly in a EU-only formula will require substitution for North American or UK post-Brexit variants. Building that constraint into the formulation brief costs nothing. Discovering it after stability studies are underway costs considerably more.

And if your commercial roadmap depends on a UV filter that isn’t yet in Annex VI, the question to ask is not “when will it be approved?” — you don’t control that timeline. The question is: what is your compliant formulation strategy in the meantime, and who is monitoring the SCCS work programme on your behalf?

At Care Europe, that kind of regulatory horizon-scanning — tracking SCCS mandates, open consultations, and amendment drafts — is part of what we do for brands building EU-facing product pipelines. Knowing that an ingredient is under active SCCS review is useful intelligence. Knowing that a favourable opinion was issued 18 months ago and the Commission amendment is expected before year-end is actionable.

The EU sunscreen market rewards brands that treat Annex VI not as a static list to check once, but as a living document that shapes what you can make, when you can make it, and how you have to prove it.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• US Sunscreen Compliance and FDA OTC Monograph Requirements — Qalitex Laboratories covers the US side of the UV filter approval gap, including FDA testing methodology and label compliance.
• Health Canada Sunscreen NPN Licensing for European Brands — Androxa outlines the Canadian natural health product pathway for sunscreen products entering the Canadian market.